Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 12, 2013, Pages 3584-3588

  Thalji, Reema K ^a   McAtee, Jeff J ^a   Belyanskaya, Svetlana ^a   Brandt, Martin ^a   Brown, Gregory D ^a   Costell, Melissa H ^a   Ding, Yun ^a   Dodson, Jason W ^a   Eisennagel, Steve H ^a   Fries, Rusty E ^a   Gross, Jeffrey W ^a   Harpel, Mark R ^a   Holt, Dennis A ^a   Israel, David I ^a   Jolivette, Larry J ^a   Krosky, Daniel ^a   Li, Hu ^a   Lu, Quinn ^a   Mandichak, Tracy ^a   Roethke, Theresa ^a   Schnackenberg, Christine G ^a   Schwartz, Benjamin ^a   Shewchuk, Lisa M ^a   Xie, Wensheng ^a   Behm, David J ^a   Douglas, Stephen A ^a   Shaw, Ami L ^a   Marino Jr , Joseph P ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

9,10 Epoxyoctadec 12(Z) enoic acid (LTX); Dihydroxyeicosatrienoic acid (DHET); Epoxyeicosatrienoic acid (EET); Leukotoxin (LTX); Soluble epoxide hydrolase; Triazine

Indexed keywords

1 [4 METHYL 6 (METHYLAMINO) 1,3,5 TRIAZIN 2 YL] N [[[4 BROMO 2 (TRIFLUOROMETHOXY)] PHENYL]METHYL] 4 PIPERADINECARBOXAMIDE; 9,10 EPOXYOCTADEC 12 ENOIC ACID; AMIDE; BIOLOGICAL MARKER; CYTOCHROME P450; EPOXIDE HYDROLASE; FUNCTIONAL GROUP; LEUKOTOXIN; LINOLEIC ACID; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; IN VIVO STUDY; NONHUMAN; RAT; SUBSTITUTION REACTION;

AMIDES; DRUG DISCOVERY; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; MODELS, MOLECULAR; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 84878114606     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.04.019     Document Type: Article

References (33)

1. R.H. Elbekai, and A.O.S. El-Kadi Pharmacol. Ther. 112 2006 564
2. J.P. Marino Jr. Curr. Top. Med. Chem. 9 2009 452
3. H.C. Shen, and B.D. Hammock J. Med. Chem. 55 2012 1789
4. A.A. Spector, and A.W. Norris Am. J. Physiol. 292 2007 C996
5. J. Bauersachs, M. Hecker, and R. Busse Br. J. Pharmacol. 113 1994 1548
6. W.B. Campbell, D. Gebremedhin, P.F. Pratt, and D.R. Harder Circ. Res. 78 1996 415
7. J.M. Seubert, C.J. Sinal, J. Graves, L.M. DeGraf, J.A. Bradbury, C.R. Lee, K. Goralski, M.A. Carey, A. Luria, J.W. Newman, B.D. Hammock, J.R. Falck, H. Roberts, H.A. Rockman, E. Murphy, and D.C. Zeldin Circ. Res. 99 2006 442
8. A. Dhanasekaran, S.K. Gruenloh, J.N. Buonaccorsi, R. Zhang, G.J. Gross, J.R. Falck, P.K. Patel, E.R. Jacobs, and M. Medhora Am. J. Physiol. 294 2008 H724
9. T.C. Nichols Drug News Perspect. 17 2004 99
10. G. Hall, J.D. Hasday, and T.B. Rogers J. Mol. Cell. Cardiol. 41 2006 580
11. N.H. Purcell, and J.D. Molkentin Circulation 108 2003 638
12. C. Freund, R. Schmidt-Ullrich, A. Baurand, S. Dunger, W. Schneider, P. Loser, A. El-Jamali, R. Dietz, C. Scheidereit, and M.W. Bergmann Circulation 111 2005 2319
13. B. Sarman, R. Skoumal, H. Leskinen, J. Rysae, M. Ilves, Y. Soini, J. Tuukkanen, S. Pikkarainen, Z. Lako-Futo, B. Sarman, L. Papp, R. de Chatel, M. Toth, H. Ruskoaho, and I. Szokodi J. Hypertension 25 2007 1927
14. H. Qiu, N. Li, J.-Y. Liu, T.R. Harris, B.D. Hammock, and N. Chiamvimonvat Cardiovasc. Ther. 29 2011 99
15. A.J. Fretland, and C.J. Omiecinski Chem. Biol. Interact. 129 2000 41
16. C. Morisseau, and B.D. Hammock Annu. Rev. Pharmacol. Toxicol. 45 2005 311
17. M. Decker, M. Arand, and A. Cronin Arch. Toxicol. 83 2009 297
18. Ota, T; Takahashi, H.; Kakinuma, H.; Busujima, T. WO2007043653A1, 2007.
19. Y. Xie, Y. Liu, G. Gong, D.H. Smith, F. Yan, A. Rinderspacher, Y. Feng, Z. Zhu, X. Li, S.-X. Deng, L. Branden, D. Vidović, C. Chung, S. Schürer, C. Morisseau, B.D. Hammock, and D.W. Landry Bioorg. Med. Chem. Lett. 19 2009 2354
20. S.J. Taylor, F. Soleymanzadeh, A.B. Eldrup, N.A. Farrow, I. Muegge, A. Kukulka, A.K. Kabcenell, and S. De Lombaert Bioorg. Med. Chem. Lett. 19 2009 5864
21. A manuscript describing ELT screening of the soluble epoxide hydrolase enzyme is in preparation.
22. A.M. Clark, R.A. Acharya, C.C. Arico-Muendel, S.L. Belyanskaya, D.R. Benjamin, N.R. Carlson, P.A. Centrella, C.H. Chiu, S.P. Creaser, J.W. Cuozzo, C.P. Davie, Y. Ding, G.J. Franklin, K.D. Franzen, M.L. Gefter, S.P. Hale, N.J.V. Hansen, N. Hansen, N. Hansen, D.I. Israel, J. Jiang, M.J. Kavarana, M.S. Kelley, C.S. Kollmann, F. Li, K. Lind, S. Mataruse, P.F. Medeiros, J.A. Messer, P. Myers, H. O'Keefe, M.C. Oliff, C.E. Rise, A.L. Staz, S.R. Skinner, J.L. Svendsen, L. Tang, K.V. Vloten, R.W. Wagner, G. Yao, B. Zhao, and B.A. Morgan Nat. Chem. Biol. 5 2009 647
23. H. Deng, H. O'Keefe, C.P. Davie, K.E. Lind, R.A. Acharya, G.J. Franklin, J. Larkin, R. Matico, M. Neeb, M.M. Thompson, T. Lohr, J.W. Gross, P.A. Centrella, G.K. O'Donovan, K.L. Bedard, K. van Vloten, S. Mataruse, S.R. Skinner, S.L. Belyanskaya, T.Y. Carpenter, T.W. Shearer, M.A. Clark, J.W. Cuozzo, C.C. Arico-Muendel, and B.A. Morgan J. Med. Chem. 50 2012 7061
24. N.M. Wolf, C. Morisseau, P.D. Jones, B. Hock, and B.D. Hammock Anal. Biochem. 355 2006 71
25. W. Xie, X. Tang, Q. Lu, R.S. Ames, S.J. Ratcliffe, and H. Li Mol. Biotechnol. 45 2010 207
26. Most analogs were screened against CYP2C8, CYP2C19, and CYP2J2 as well. Little or no inhibition was observed at 10 μM concentration.
27. J. Seidegård, J. DePierre, and R. Pero Cancer Res. 44 1984 3654
28. A.J. Draper, and B.D. Hammock Toxicol. Sci. 50 1999 30
29. M. Hayakawa, S. Sugiyama, T. Takamura, K. Yokoo, M. Iwata, K. Suzuki, F. Taki, S. Takahashi, and T. Ozawa Biochem. Biophys. Res. Commun. 1986 424
30. Data not obtained for 27, however structurally analogous compounds possess half-lives up to 60 min.
31. Kompa, A R.; Wang, B. H.; Xu, G.; Zhang, Y.; Ho, P. Y.; Eisennagel, S.; Thalji, R. K.; Marino, J. P., Jr.; Kelly, D. J.; Behm, D. J.; Krum, H. Int. J. Cardiol., in press.
32. The X-ray coordinates have been deposited in the RCSB Protein Data Bank (PDB). Code is 4JNC.
33. H.C. Shen, F.-X. Ding, S. Wang, Q. Deng, X. Zhang, Y. Chen, G. Zhou, S. Xu, H. Chen, X. Tong, V. Tong, K. Mitra, S. Kumar, C. Tsai, A.S. Stevenson, L.-Y. Pai, M. Alonso-Galicia, X. Chen, S.M. Soisson, S. Roy, B. Zhang, J.R. Tata, J.P. Berger, and S.L. Colletti J. Med. Chem. 52 2009 5009